Protective Immunity of 56-kDa Type-Specific Antigen of Orientia tsutsugamushi Causing Scrub Typhus
Protective Immunity of 56-kDa Type-Specific Antigen of Orientia tsutsugamushi Causing Scrub Typhus
复制标题
DOI：
10.4014/jmb.1407.07048
复制
发表时间：
2014-12-01
影响因子：
2.8
通讯作者：
Lee, Jeongmin
中科院分区：
文献类型：
--
作者：
Choi, Sangho;Jeong, Hang Jin;Lee, Jeongmin
恙虫病是由恙虫病东方体感染引起的一种人畜共患疾病，在亚太地区流行。在韩国，这种疾病的发病率随着气候变化而增加，2013年报告的感染病例超过10 000例。虽然这种感染是可以治疗的抗生素，如强力霉素和阿奇霉素，一个有效的预防性疫苗对O。恙虫病在地方病流行区预防恙虫病更理想。在这项研究中，我们研究了56-kDa型特异性抗原（TSA 56），这是一个主要的外膜蛋白的O。恙虫病作为候选疫苗。重组TSA 56（rec 56）鼻内免疫诱导的TSA 56特异性IgG水平高于肌肉内免疫的tsa 56表达DNA（p56）诱导的水平。这两种类型的免疫诱导细胞介导的免疫应答TSA 56，如脾细胞增殖试验所示。用p56免疫小鼠，然后用rec 56加来自E.大肠杆菌，对O.恙虫病Boryong株与其他组合。我们的初步研究结果表明，一个有效的人用疫苗恙虫病可以包括重组TSA 56蛋白或TSA 56表达的DNA，并提供了进一步的研究，以优化疫苗的性能，使用额外的抗原或不同的佐剂的基础。
Scrub typhus, caused by infection with Orientia tsutsugamushi, is a mite-borne zoonotic disease endemic to the Asian-Pacific region. In Korea, the incidence of this disease has increased with climate changes, and over 10,000 cases of infection were reported in 2013. Although this infection is treatable with antibiotics such as doxycycline and azithromycin, an effective prophylactic vaccine against O. tsutsugamushi would be more desirable for preventing scrub typhus in endemic areas. In this study, we investigated the 56-kDa type-specific antigen (TSA56), which is a major outer membrane protein of O. tsutsugamushi, as a vaccine candidate. Intranasal immunization of recombinant TSA56 (rec56) induced a higher level of TSA56-specific IgG than that induced by intramuscular immunization of tsa56-expressing DNA (p56). Both types of immunization induced a cell-mediated immune response to TSA56, as demonstrated by the splenic cell proliferation assay. Mice immunized with p56, followed by rec56 plus heat-labile enterotoxin B subunit from E. coli, had a stronger protection from a homologous challenge with the O. tsutsugamushi Boryong strain than with other combinations. Our preliminary results suggest that an effective human vaccine for scrub typhus can include either recombinant TSA56 protein or tsa56-expressing DNA, and provide the basis for further studies to optimize vaccine performance using additional antigens or different adjuvants.